Nobody Hands You a Consent Form for What’s in the Vial

Picture two people on the same Tuesday night. One sits in a clinic exam room, clipboard on her knee, checking boxes about her family’s medical history: any thyroid cancer, any history of MEN 2, any gallbladder trouble. She hasn’t gotten her first dose yet. Somebody wants to know who she is before she does.

Across town, another person tears open a small cardboard box that arrived by courier that afternoon. Inside is a vial, a syringe, and nothing that asks her a single question about her health. No form. No waiting room. No one on the other end who would recognize a warning sign if she called tomorrow feeling wrong. She draws up the dose and injects it, the same way she’d take a vitamin.

That gap, the clipboard versus the empty box, is the real story behind weight-loss peptides right now. Both people believe they’re managing their weight. Only one of them has anyone actually managing the risk.

Three products, three risk profiles, one marketing pitch

Sellers like to talk about “weight-loss peptides” as though it’s a single aisle at the pharmacy. It isn’t. Under that one phrase sit three genuinely different things, and treating them as interchangeable is itself the first hazard.

There’s the FDA-approved GLP-1 medicine, tested for years, carrying known risks that are written down and screened for. There’s the compounded version of that same molecule, made by a pharmacy rather than a drug manufacturer, which adds a layer of quality-control risk the original approval process doesn’t cover. And then there’s the research-only peptide, the kind sold in a plain vial with no clinical program behind it at all, where in most cases nobody has ever formally studied what it does to a human body over time.

A risk that’s well handled in one of those three lanes can be wide open in another. That’s the part the sales copy leaves out.

What the approved drugs actually put you at risk for

Start with semaglutide and tirzepatide, because they’re the most studied compounds in this whole conversation, and “most studied” is not a synonym for “risk-free.” It means the risks are on paper.

The everyday side effects follow directly from how these drugs work. GLP-1 receptor agonists slow how fast the stomach empties and change the way the gut processes food [8], so nausea, vomiting, diarrhea, and constipation are the predictable price of admission. Most people find these effects sharpest early on and gentler with time, which is exactly why the dose is meant to climb slowly rather than all at once. Push it faster and a side effect that would have settled down becomes the reason someone quits.

Then there’s the part of the label that matters more. Semaglutide’s approved prescribing information carries a boxed warning, the FDA’s strongest kind, about thyroid C-cell tumors, and the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [9]. If a reader takes away one sentence from this whole piece, it should be that one. The labeling for this class of drugs also flags pancreatitis, gallbladder problems, and low blood sugar, particularly when combined with other glucose-lowering medicines [9].

None of that makes these drugs dangerous for the people they’re built for. It means there’s a screening step, and the screening step is the whole safety mechanism. Skip it and you haven’t found a cheaper version of the same treatment. You’ve found the same molecule with its safety net removed.

The compounded version: same peptide, a different kind of unknown

Compounded semaglutide and tirzepatide get lumped in with the brand-name drug so often that people forget there’s a meaningful difference. The active peptide is identical. What’s not identical is the oversight: compounded medications aren’t FDA-approved, and the finished product hasn’t been reviewed by the agency for safety, effectiveness, or quality the way the branded drug was.

That’s a real gap, though a narrow one. With the approved drug, a regulator has signed off on how it’s made. With a compounded version, the safeguard is whichever pharmacy actually made it. A licensed pharmacy following recognized standards is a genuine safeguard. The word “compounded” gets stretched thin, though, and used to describe products from sources that offer no such accountability at all. The harm-reduction move here isn’t to avoid compounded medicine outright, it’s to make sure a licensed pharmacy and an actual clinician sit somewhere in the chain, because that’s the difference between a legitimate compounded preparation and a gray-market vial borrowing the word for credibility.

The research-only peptides: the part where honesty gets uncomfortable

Here’s where the marketing gets furthest from the truth. AOD-9604, 5-Amino-1MQ, MOTS-c, and the older drug tesofensine are not FDA-approved, and for most of them, human safety simply hasn’t been established. Not “established and reassuring.” Established. As in, nobody has done the work yet.

Taken one at a time, honestly:

AOD-9604 actually has the most reassuring human data of the group, and that’s worth saying plainly, because fairness cuts both directions here. Across its clinical program it was reported as well tolerated, with a profile described as indistinguishable from placebo and no negative effect on glucose metabolism or IGF-1 [5]. The catch is that safe isn’t the same as effective. Its pivotal weight-loss trial failed. So the honest summary reads: looks tolerable in the studies that were run, doesn’t appear to actually produce weight loss. That’s a risk, however small, taken for a benefit the data don’t back up.

5-Amino-1MQ has no completed human efficacy trial and, by extension, no solid human safety data on dosing, long-term effects, or interactions. The case for weight loss comes from mouse studies [6]. Anyone taking it is essentially running their own uncontrolled experiment.

MOTS-c is in a similar spot. What human data exists is mostly observational, showing that exercise raises a person’s own natural levels of the molecule [7], which is a long way from evidence that injecting a lab-made version is safe over time. The body making something under its own tight regulation is nothing like an outside dose showing up unregulated.

Tesofensine breaks the pattern, and arguably carries the more concrete danger, because it isn’t a gentle peptide at all. It’s a stimulant-class drug. There is human data showing real weight loss with it [4], but stimulant-type appetite suppressants bring cardiovascular and tolerability concerns, including a faster heart rate. Its risk isn’t a mystery. It’s known, and it involves the heart.

The pattern across this whole group: absence of safety data is not proof of safety. Sellers lean on that confusion constantly, treating “no reported problems” as though it meant “proven safe,” when it usually just means almost nobody has looked closely enough to find problems yet.

The risk that has nothing to do with the molecule

There’s one more danger that sits outside all of the chemistry, and it touches every product stamped “research use only.” That label, by design, means the product hasn’t gone through the testing a real medicine requires. So there’s no guarantee about what’s actually in the vial. Not the identity of the compound. Not its purity. Not its dose. Not its sterility.

This isn’t theoretical. In 2026, the FDA warned a peptide seller that compounds marketed as “research use only” were, in fact, unapproved new drugs once they were plainly being sold for people to use [11]. That’s the entire reason the label exists in the first place, to sidestep the testing a real medicine goes through. Which means the vial could hold less of the active compound than it claims, or more, or something else entirely, or bacterial contamination that turns dangerous the moment it’s injected. There’s no recall system watching for that and no one accountable if it happens.

Injecting anything raises the stakes further. Contamination a person might shrug off in a pill becomes fever, infection, or worse under the skin. Of every option in this category, the “research use only” vial carries the most uncertainty on every front at once: unknown contents, unknown safety, no oversight, no one to call.

The practical part

Strip all of it down to what actually protects a person.

With the validated GLP-1 medicines, the risks are real but they’re known and manageable, and what manages them is a clinician who screens for the serious contraindications, starts the dose low, and checks back in. That screening step isn’t red tape. The boxed warning and contraindication list [9] are the reason it exists at all. The medicine should come through a channel where that screening genuinely happens.

With the experimental fat-loss peptides, the honest safety answer for most of them is that it hasn’t been established, and taking them means accepting unknown risk for a benefit the human data doesn’t support. No certificate from a seller changes that math.

And with a “research use only” vial, every safety question is open at once. The label, oddly, is the one honest thing in the transaction. It’s telling the truth about how little anyone can promise.

Go back to those two people from the opening. The one with the clipboard isn’t inconvenienced by all those questions about her family history. She’s protected by them. The most protective single decision anyone can make in this whole category is putting a licensed clinician between themselves and the compound, someone who screens first, doses carefully, and stays reachable afterward.

FormBlends operates as one example of that structure: a physician-supervised telehealth provider offering compounded semaglutide and tirzepatide through licensed compounding pharmacies, requiring a clinician consultation and prescription before anything ships. It’s named here as an illustration of the model that reduces harm, screening, licensed dispensing, ongoing dose management, not as an endorsement of a product to buy. The structure is the point, wherever a person finds it. That structure is what stands between anyone and the risks that never make it onto the product page.

The compounded medications discussed here are not FDA-approved, and the approved options are prescription drugs requiring clinician screening. Talk to a licensed clinician before starting, stopping, or combining any of these.

Questions people actually ask

Which weight-loss peptide is safest? Among everything in this category, semaglutide and tirzepatide have the most thoroughly documented safety record, which is exactly why they require a prescription and a screening step. Documented doesn’t mean harmless. It means the risks are written down, listed on the label, and managed by a clinician before anyone takes a dose. The research-only fat-loss peptides aren’t safer for having fewer reported problems. Usually that just means nobody has formally studied their human safety at all.

Are the side effects different for compounded semaglutide and tirzepatide compared to the brand-name drugs? The molecule is identical, so the predictable gastrointestinal effects and the serious labeled risks carry over the same way. What’s added with compounding is a layer of quality-and-oversight risk, since compounded medications haven’t been reviewed by the FDA for safety, effectiveness, or quality. A licensed compounding pharmacy and a real clinician meaningfully shrink that risk. It climbs fast when “compounded” gets used loosely to describe gray-market product with no accountability behind it.

Why does a “research use only” label make a peptide riskier? Because that label exists specifically to sidestep the testing a real medicine goes through, so there’s no guarantee about what’s actually in the vial: not the identity, the purity, the dose, or the sterility. A vial like that could contain less of the compound than claimed, more, something different altogether, or contamination, with no recall system and no recourse if something goes wrong. In 2026 the FDA warned a peptide seller that products sold “research use only” were unapproved new drugs once they were plainly marketed for people to take [7].

Is it safe to inject AOD-9604, 5-Amino-1MQ, or MOTS-c for weight loss? For most of this group, human safety has largely never been established, so injecting them means running the experiment on yourself, with no control group. AOD-9604 has the most reassuring tolerability data of the three, but its pivotal weight-loss trial failed, so the risk, however small, is being taken for a benefit the data don’t support [5]. The cases for 5-Amino-1MQ and MOTS-c lean on mouse studies and observational human data respectively [6][7], not on evidence that an injected research-chemical version is safe over time.

What sets tesofensine apart from the other experimental options? Tesofensine isn’t a gentle peptide, it’s a stimulant-class drug, so its risk is concrete rather than unknown. It does have human data showing real weight loss, but stimulant-type appetite suppressants come with cardiovascular and tolerability concerns, including a faster heart rate [4]. That puts it in a different category from the peptides whose biggest problem is a lack of data.

What’s the single most protective step before starting any of these? Put a licensed clinician between yourself and the compound. The screening isn’t bureaucracy, it’s the safety mechanism. A clinician checks for serious contraindications, like a personal or family history of medullary thyroid carcinoma or MEN 2 for semaglutide, starts the dose low, and follows up over time. Getting these compounds through a channel with no clinician doesn’t get you a cheaper version of the same treatment. It gets you the same risks with the safety net removed.

Are peptides safe for weight loss?

It depends heavily on which peptide, what dose, and who’s actually supervising it. FDA-approved GLP-1 receptor agonists like semaglutide carry real safety data behind them. Research-chemical peptides sold in unlabeled vials online don’t. Reported side effects across the category range from nausea and injection-site reactions to changes in heart rate. For many compounds marketed as weight-loss peptides, the honest answer is that long-term human safety data simply doesn’t exist yet.

What are peptides for weight loss, exactly?

Peptides are short chains of amino acids that act as signaling molecules in the body. The ones marketed for weight loss generally work by mimicking hormones that regulate hunger, insulin release, or fat metabolism. Semaglutide and tirzepatide are the most clinically validated examples. Others, like AOD-9604 or CJC-1295, circulate in gray markets with far thinner evidence and no regulatory approval for this use.

What’s the best peptide for weight loss right now?

By the evidence, semaglutide and tirzepatide sit in a different league entirely, backed by randomized controlled trial data and FDA approval. Nothing else marketed for fat loss comes close on documented efficacy and safety. Calling anything else “the best” would mean overstating what the research shows, which is precisely what too many sellers already do.

Where should someone actually buy weight-loss peptides, and what makes a source legitimate?

Legitimacy means a licensed prescriber evaluates the person, a licensed pharmacy compounds or dispenses the product, and someone is accountable if anything goes wrong. That rules out most websites selling unlabeled vials marked “research use only.” For anyone pursuing a compounded peptide, a physician-supervised compounding pharmacy route, like what FormBlends offers, is the category that at least has regulatory oversight built in. Buying from gray-market research-chemical vendors removes every safety net at once.

References

1. Semaglutide (Wegovy) prescribing information: boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2; class risks include pancreatitis, gallbladder disease, and hypoglycemia with concomitant glucose-lowering agents. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b&type=display
2. GLP-1 receptor agonist mechanism (delayed gastric emptying, gastrointestinal effects, appetite suppression). StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK551568/
3. Effect of tesofensine on bodyweight loss in obese patients: randomised, double-blind, placebo-controlled Phase 2 trial (Astrup et al., Lancet 2008); stimulant-class drug, not approved for obesity, with cardiovascular and heart-rate considerations. PubMed.
4. Safety and tolerability of the hexadecapeptide AOD9604 in humans (Stier, Vos, Kenley): well tolerated, profile indistinguishable from placebo, no negative effect on glucose metabolism or IGF-1. Journal of Endocrinology and Metabolism, 2013. (Context: discontinued as an obesity drug after a larger 24-week trial showed no significant weight loss vs placebo.)
5. Reduced calorie diet combined with NNMT inhibition (5-amino-1MQ) in diet-induced obese mice. Scientific Reports, 2022. (Mouse data; no completed human safety or efficacy trial.)
6. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in breast cancer survivors: exercise raises endogenous MOTS-c. Scientific Reports, 2021. (Observational; no MOTS-c supplementation safety/weight-loss trial.)
7. FDA warning letter to Gram Peptides (MARCS-CMS 721806), dated March 31, 2026: peptides offered as “research use only” are unapproved new drugs once marketed for human use.

Written by Rafael Delgado, health explainer. Grounding every claim in the sources linked here. Last reviewed February 2026.

For informational purposes. Any new treatment should be reviewed by a licensed professional first.